Platinum-resistant ovarian cancer: Prematurely stopped phase II Austrian AGO chemotherapy studies

Table 4 Commonly used systemic therapy regimens in patients with platinum-resistant or platinum-refractory ovarian cancer

Chemotherapy regimen	Dose	Interval	Remarks
PEG-liposomal doxorubicin	40-45 mg/m2 per day iv	day 1 every 4 wk	No alopecia, non-significant nausea/emesis, minor myelosuppression, significant hand-foot syndrome in 10% to 20%, respectively
Paclitaxel weekly	80 mg/m2 per day iv (1-h-infusion)	Once weekly for three doses followed by 2 wk rest	Complete alopecia, no peroral premedication with dexamethasone necessary, minor myelosuppression, less neurotoxicity compared with 3-weekly paclitaxel
Gemicitabine	1000-1250 mg/m2 per day iv	Days 1 + 8 every 3 wk	No alopecia, minor nausea/emesis, significant myelosuppression
Topotecan weekly	4 mg/m2 per day iv	Days 1, 8, 15 every 4 wk	Moderate myelosuppression, rarely emesis/nausea, rarely significant alopecia
Bevacizumab	15 mg/kg per day iv	Day 1 every 3 wk	Significant hypertension, gastrointestinal perforations in up to 11%
Tamoxifen	20 mg/d	Daily	Response rate around 10%, mild toxicity

iv: Intravenously; PEG: Pegylated.